Alvotech (ALVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human use adopted a positive opinion recommending approval for AVT03, Alvotech’s proposed biosimilar to Prolia and Xgeva. Pending approval, the biosimilar will be marketed by Alvotech’s commercial partners, STADA Arzneimittel and Dr. Reddy’s Laboratories (RDY), each partner with semi-exclusive commercial rights in Europe, including Switzerland and the UK. AVT03 remains under EMA regulatory review with a final decision by the European Commission pending.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: